The improved applied Biosystems HIV-1 Genotyping Kit was released by Thermo Fisher Scientific, Inc. The new kit complements the previously released Applied Biosystems MagMax Viral/Pathogen Nucleic Acid Isolation Kit for HIV-1 Blood Sports. With the aid of this device, labs may monitor HIV mutations to antiretroviral treatment inhibitors using a cutting-edge method for drug resistance surveillance.
The BD Rhapsody TCR/BCR Multiomic Assay, a cutting-edge set of reagents that enables researchers to more easily and thoroughly analyze crucial immune system cells, was released by BD (Becton, Dickinson, and Company), a leading global medical technology company. This assay would then be used to advance research on autoimmune disorders, immune oncology, and infectious diseases.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 4785
Published Date: Sep 28, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The majority factors driving the growth of the market are growing geriatric population, rise in prevalence of cancer, surge in need for stem cell transplant, and others.
The market size of cell viability assays is anticipated to attain a CAGR of 11.5% over the forecast period, i.e., 2024 â€“ 2036.
The major players in the market are Agilent Technologies, Inc., Bio-Rad Laboratories Inc., Merck KGaA, Becton, Dickinson and Company (BD), PerkinElmer Inc., Promega Corporation, Biotium, Inc., Creative Bioarray, Abcam Plc., and others.
The stem cell research segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.